Noël, Christian <br/><br/>
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.  [electronic resource] 

 -  Journal of the American Society of Nephrology : JASN  Jun 2009 
 - 1385-92 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1533-3450 
<br/><br/><label>Standard No.: </label>10.1681/ASN.2008101037  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antilymphocyte Serum--therapeutic use<br/>Biopsy<br/>Daclizumab<br/>Female<br/>Graft Rejection--pathology<br/>Humans<br/>Immunoglobulin G--therapeutic use<br/>Immunosuppressive Agents--therapeutic use<br/>Kidney--pathology<br/>Kidney Transplantation<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Risk Factors<br/>Treatment Outcome